UroGen Pharma Announces 82.3% 12-Month Duration Of Response In Phase 3 ENVISION Trial For UGN-102; Achieved 79.6% Complete Response Rate At Three Months
Portfolio Pulse from Benzinga Newsdesk
UroGen Pharma announced positive results from its Phase 3 ENVISION trial for UGN-102, showing an 82.3% 12-month duration of response and a 79.6% complete response rate at three months. The side effect profile was consistent with previous trials.
June 13, 2024 | 2:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UroGen Pharma's Phase 3 ENVISION trial for UGN-102 demonstrated an 82.3% 12-month duration of response and a 79.6% complete response rate at three months, with a side effect profile consistent with previous trials.
The positive results from the Phase 3 ENVISION trial for UGN-102 are likely to boost investor confidence and positively impact UroGen Pharma's stock price in the short term. The high response rates and consistent side effect profile are strong indicators of the drug's potential success.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100